Why did SLDB's Q3 2023 earnings miss forecasts so drastically?

Solid Biosciences' Q3 2023 earnings missed forecasts due to **Increased Operating Expenses and Negative Net Income**:

1. **Heightened Research and Development Activities**: The company's operating expenses surged because of intensified research and development activities. This increase was likely driven by the need to advance their gene therapy candidates, such as SGT-003 for Duchenne muscular dystrophy, through clinical trials.
2. **Financial Position and Future Prospects**: Despite the increased losses, Solid Biosciences strengthened its financial position by raising substantial funds through private placements and public offerings. These financial resources are crucial for supporting ongoing operations and future growth initiatives.

In summary, the miss in earnings can be attributed to the high costs associated with research and development, which are common in the biotech sector, despite the company's strategic efforts to strengthen its financial position.